

Vaishali Pharma Ltd.



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : sales@vaishalipharma.com
CIN - L52310MH2008PLC181632

28/06/2021

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai - 400 051

Stock Code: VAISHALI

Dear Sir/Madam,

SUB: THE COMPANY HAS RECEIVED MULTIPLE ORDERS FROM VARIOUS COUNTRIES.

We are very pleased to inform our shareholders that after continuous diligent work and planned marketing strategies, *the Company has received orders from Nicaragua and a preliminary order from Madagascar for the supply of our various Antibiotics and other generic medicines such as painkillers etc.*

Please find enclosed herewith a copy of Press Release giving information about the same and many more.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,
For Vaishali Pharma Limited



Atul Arvind Vasani
Managing Director

PRESS RELEASE

THE COMPANY HAS RECEIVED MULTIPLE ORDERS FROM VARIOUS COUNTRIES.

Mumbai, June 28, 2021: Vaishali Pharma Limited (NSE:- VAISHALI), a Mumbai based Company, engaged in supply of pharmaceutical products to corporates, hospitals and retails stores in all SKUs required. Our products have made its grasp on the overseas market and getting an excellent feedback worldwide. The Company is showing consistent agility and innovation by meeting the needs of its customers in both Domestic and International markets.

Vaishali Pharma has predominantly built portfolio into bulk Drugs / APIs, formulation, Surgical products, Veterinary products, Herbal & Nutraceutical products. The company is striving hard to double the product range in coming years and this is considered to be just the beginning.

We had been persistently making application for registering our products in the international market domain and with the help of our team's continuous diligent work and planned marketing strategies we have successfully received registrations of our various products and we are expecting many more registrations soon.

The company has supplied many of its registered products to various countries, and has received very good response for its quality, timely delivery of the products and services. Furthermore, we are very pleased to inform our shareholders that after constant hardworking, intended marketing strategies and with such worthy feedbacks, ***the Company has received orders from Nicaragua and a preliminary order from Madagascar for the Supply of our registered products including various Antibiotics and other generic medicines such as painkillers etc.***

Nicaragua is located in Central America and borders Honduras, Costa Rica, and the Atlantic and Pacific Oceans. It has limited domestic manufacturing capabilities and majority of pharmaceuticals and medical equipment are imported. The majority of diseases include high food or waterborne diseases, bacterial diarrhea, malaria, leptospirosis, Hepatitis A, and typhoid fever, dengue fever.

In Nicaragua, the Local Manufacturing is limited and the markets are import driven, and thus creating huge opportunities for our company. The pharmaceutical market value is approximately USD 475 Mn with location production being less than 20%. The compound annual growth rate stands at 4.5%.

Madagascar, officially the Republic of Madagascar, and previously known as the Malagasy Republic, is an island country in the Indian Ocean, approximately 400 kilometres off the coast of East Africa across the Mozambique Channel. The government's public health policy seeks to establish universal health care coverage for children under age five, pregnant women, and people over 65. It prioritizes the provision of adequate and modern equipment and identifies the need to increase the public health budget. The diseases which are highly prevalent in Madagascar, includes cholera, malaria, dengue, chikungunya fever, pneumonia, schistosomiasis (bilharzia), leprosy, rift valley fever, meningitis, and syphilis. HIV/AIDS and tuberculosis are prevalent in Madagascar but are relatively low in comparison to countries within the African continent.

In Madagascar, the pharmaceutical industry is expanding and the Imports of Pharmaceutical products was USD 142.61 Million during 2019 and the African pharmaceutical markets are growing in every segment, given that between 2017 and 2030, prescription drugs are forecast to grow at a compound annual growth rate of 6.5%, generics at 10%, over-the-counter medicines at 7.1%, and medical devices at 12.1% is expected to grow in the upcoming years. Hence, we expect great beneficial progress from such expanding markets.

We at Vaishali Pharma will further strengthen the Company's presence in Nicaragua and Madagascar as

well as enhance stronger relations with our clients and the **Nicaragua Ministry of Health / Ministerio de Salud de la República de Nicaragua.**

ABOUT VAISHALI PHARMA LIMITED:

Vaishali Pharma Limited (NSE: VAISHALI), abided by the norms of extending uncompromised quality products, has raised the standards of the Pharmaceutical & Healthcare industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

In business since 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 150+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai.

At Vaishali Pharma, we are working tirelessly to make available health improving pharmaceutical products affordable and accessible to all. Looking beyond this immediate term, the upcoming half year shall present more good opportunities for the Company and we shall continue to perform better than the previous half year.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects. One can count upon us for quality pharmaceutical and healthcare products.

For more details please visit: www.vaishalipharma.com

For any Investor Relations query, please contact:

Mr. Akshay Jharkhandi
Company Secretary

Email: cs@vaishalipharma.com

Mr. Ratnesh Singh
Chief Financial Officer

Email: investor@vaishalipharma.com

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.